TIDMHEMO

RNS Number : 5133E

Hemogenyx Pharmaceuticals PLC

12 February 2018

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Director / PDMR Shareholding

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1     Details of the person discharging managerial 
        responsibilities / person closely associated 
----  ----------------------------------------------------------------- 
 a)    Name                            Adrian Beeston 
----  ------------------------------  --------------------------------- 
 2     Reason for the notification 
----  ----------------------------------------------------------------- 
 a)    Position/status                 Non-executive Director 
----  ------------------------------  --------------------------------- 
 b)    Initial notification            Initial notification 
        /Amendment 
----  ------------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, auctioneer 
        or auction monitor 
----  ----------------------------------------------------------------- 
 a)    Name                            Hemogenyx Pharmaceuticals 
                                        Plc 
----  ------------------------------  --------------------------------- 
 b)    LEI                             n/a 
----  ------------------------------  --------------------------------- 
 4     Details of the transaction(s): section to 
        be repeated for (i) each type of instrument; 
        (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions 
        have been conducted 
----  ----------------------------------------------------------------- 
 a)    Description of                  Ordinary shares of GBP0.01 
        the financial                   each 
        instrument, type 
        of instrument 
---- 
 
       Identification                  ISIN GB00BYX3WZ24 
        code 
 
 b)    Nature of the                   Purchase of Ordinary Shares 
        transaction 
----  ------------------------------  --------------------------------- 
 c)    Price(s) and volume(s) 
----                                   --------------  -------------- 
                                        Price(s)        Volume(s) 
----                                   --------------  -------------- 
                                        2.1p            200,000 
                                       --------------  -------------- 
 
 d)    Aggregated information 
---- 
 
  - Aggregated volume              N/A - single transaction 
 
  - Price 
 
 e)    Date of the transaction         9 February 2018 
----  ------------------------------  --------------------------------- 
 f)    Place of the transaction        London Stock Exchange 
----  ------------------------------  ---------------------------------

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBIGDDDDGBGIC

(END) Dow Jones Newswires

February 12, 2018 02:00 ET (07:00 GMT)

Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Hemogenyx Pharmaceuticals Charts.
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Hemogenyx Pharmaceuticals Charts.